Navigation Links
Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
Date:3/12/2008

other things, for filing patents to protect the MT-39 series based both on the original work performed at MTI as well as work that will be carried out by Makoto.

Terence S. Russell, Ph.D., President and CEO of Makoto, said: "We are very pleased to have the opportunity to work with Mercury and to apply Makoto's expertise in small molecule target identification to drug discovery in metabolic disease. Type-2 diabetes is a large and growing serious medical condition for which novel therapeutics are increasingly needed."

Neal C. Birnberg, Ph.D., Mercury Therapeutics' President and CEO, said: "By finding a development partner for the MT-39 program while continuing to develop direct AMPK activators in-house, this agreement with Makoto complements Mercury's internal AMPK activator development strategy. Furthermore, by leveraging our AMPK small molecule discovery platform to identify both direct and indirect AMPK activators, this agreement increases the number of potential revenue generating opportunities for our shareholders."

About Mercury Therapeutics, Inc. (http://www.mtipharm.com)

MTI was launched in 2001, and has an exclusive license to a patent from Dartmouth College and St. Vincent's Institute for Biomedical Research in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D operations following execution of a sub-license and collaboration agreement with Aventis to develop AMPK activators to treat Type-2 diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and the AMPK collaboration with MTI ended. In October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4 2005, MTI demonstrated its first preclinical proof-of-principle of active compounds in a glucose tolerance test in mice. In Q4 2006, MTI implemented a chemical design and synthesis program which led to the submission of a patent application in February 2008 cla
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
3. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
4. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
5. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
6. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
7. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
8. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
9. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
10. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
11. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today ... small cell cervical cancer (SCCC) that shows ... the company,s panomic, comprehensive tumor profiling service, identified ... may explain sensitivities and resistance to common ... certain biomarkers may guide treatment strategies in ...
(Date:3/27/2015)... 27. März 2015  Peter Walter wurde ... Science für seine bahnbrechende Arbeit ausgewählt, die ... transportiert werden, sowie für die Entschlüsselung der ... auf Stress nutzen, der mit der Ansammlung ... Professor für Biochemie an der University of ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics ... announced that after dealing with certain matters, including the ... shareholders held on March 26, 2015 (the "Meeting") was ... April 8, 2015 at 11:00 a.m. ( Toronto ... has been changed from that previous disclosed. The Meeting ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Former Pfizer executives to lead regulatory affairs group based in Ann ... ... 25 United BioSource Corporation,(UBC) today announced the expansion of its ... Lang, Dr PH. Based,in Ann Arbor, Michigan, the group will provide ...
... CRT-D and upgraded ... System, NATICK, Mass., Feb. 25 Boston Scientific,Corporation (NYSE: ... three products in its Cardiac Rhythm Management,business. They are:, ... helps protect patients at risk of sudden cardiac ...
... 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... first Phase 3 clinical trial with AZ-004 ... being developed for the treatment of,acute agitation ... Alexza,believes the novel, non-invasive nature and rapid ...
Cached Biology Technology:United BioSource Expands Regulatory Affairs Capabilities 2Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 2Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 3Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... While hunting among chimpanzees is a group effort, key males, ... They are more likely to initiate a hunt, and hunts ... The findings, which appear in the current issue of ... cooperate to hunt for food, and how individual variation among ...
... computational approach could speed up the process and cut ... the University of Chicago Medical Center and Columbia University ... February 2008 issue of Genome Research, available early online. ... genes and proteins that serve as targets for nearly ...
... the University of Southern California have developed a prostate ... 90 percent of young mice genetically predestined to develop ... Cancer Research, they suggest the same strategy might work ... antigen), a potential diagnostic indicator of prostate cancer. ...
Cached Biology News:Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Study of successful drug targets could hasten development of new medications 2Study of successful drug targets could hasten development of new medications 3Prostate cancer: Watchful wait or vaccinate? 2Prostate cancer: Watchful wait or vaccinate? 3
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
Biology Products: